Ropsacitinib 7 (PF-06826647)35 is an adenosine triphosphate (ATP) mimic TYK2-selectiveinhibitor that displayed efficacy in a phase 2b psoriasis trial.36 More recently, new TYK2 inhibitors have beendescribed or announced, notably, 8 (zasocitinib)—anallosteric TYK2-selective inhibitor—which was described aseffective in a small phase 1b study in psoriasis patients37 and in a phase 2b study,38 and VTX958,39 which is alsoan allosteric inhibitor that just completed a phase 1 study in healthyvolunteers.39 Here, TYK2 is linked to psoriasis.